Ensuring Product Quality and Managing Risk: Validate, Verify, Implement - Biopharmaceutical companies must follow an active approach to managing their supply chains. - BioPharm International

ADVERTISEMENT

Ensuring Product Quality and Managing Risk: Validate, Verify, Implement
Biopharmaceutical companies must follow an active approach to managing their supply chains.


BioPharm International
Volume 22, Issue 7


Ellen Leinfuss
The global economy has changed the way business is conducted, with a supply chain of dispersed facilities, outsourced functions, and subcontractors replacing the traditional corporate model of vertical integration. Global supply chains routinely cross national borders and can involve dozens of subcontractors.

Last year's heparin tragedy was caused by multiple quality breakdowns in the supply chain, from the sourcing of pure heparin to inadequate product testing and supplier oversight. The breakdowns occurred under the watch of the active pharmaceutical ingredient (API) manufacturer, the contract manufacturer, the sponsor company, and even the US Food and Drug Administration (FDA). Regardless of who may have "failed" in performing their responsibilities, it is the sponsor company that carries ultimate responsibility for the quality of the product and liability for the consequences to patients.

Ensuring product quality should not rely only on certifications by suppliers or inspections by the FDA. To ensure product quality, sponsor companies must follow a three-pronged approach to managing their supply chains: "validate, verify, and implement."

VALIDATE

Is the entire manufacturing, software, and quality system capable of protecting product quality and compliance? Validation should be conducted for the entire supply chain to confirm that all interrelated systems are properly designed, installed, calibrated, maintained, and tested to ensure consistent operation and performance. Recent examples of failures focus on the lack of consistent test procedures or laboratory control mechanisms, calibration of manufacturing equipment, and the accuracy of output from computer or production systems.

VERIFY

Does each link in the supply chain have the necessary procedures in place to fulfill its quality and compliance responsibilities? Standard operating procedures (SOPs) are the basis of good manufacturing practice, yet poor or nonexistent SOPs are often the subject of 483s and warning letters from the FDA. All SOPs, policies, and written procedures must be verified. Testing procedures must be verified to ensure that any failure in one part of the supply chain will be identified and corrected where it occurs. Breakdowns in procedures, and the inability to identify those breakdowns quickly, are at the root of most compliance violations and product quality issues.

IMPLEMENT

Are the systems being operated according to SOPs and corporate policy? SOPs and policies are useful only if people are able to effectively implement them. Have employees (not only those of subcontractors, but also of their subcontractors) been properly trained? Have knowledge gaps been identified and closed? Can each member of the supply chain demonstrate compliance with not only regulatory requirements, but also the sponsor company's code of conduct, ethical standards, and compliance responsibilities?

Ensuring product quality becomes more difficult by the day as supply chains extend into new parts of the world and subcontractors release work to a growing network of small, often hidden, providers. It is our responsibility as professional managers overseeing the development and distribution of drugs to the public to vigilantly focus on quality, consistency, and positive patient outcomes, regardless of the size and complexity of the supply chain.

Ellen Leinfuss is a senior vice president at Kaplan EduNeering, Princeton, NJ, 609.627.5300,

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines
Source: BioPharm International,
Click here